Belite Bio Inc (STU:D01)

Q3 2025 Belite Bio Inc Earnings Call Transcript

Nov 10, 2025 / 09:00 PM GMT

Release Date Price: €96 (+1.05%)

Transcript

Key Points

Positve

Belite Bio Inc (BLTE) completed the enrollment of the phase 3 Phoenix trial with 530 subjects, marking significant progress in their clinical trials.
The company has completed the phase 3 Dragon trial for Stargardt's disease and plans to report final topline data by the end of the month.
Positive feedback from regulatory authorities, including China's NMPA and the UK's MHRA, supports the potential for global submissions and approvals.
Belite Bio Inc (BLTE) successfully completed a $50 million registered direct offering and a $125 million private placement, strengthening their financial position.
The company has $275.6 million in cash, liquidity fund, time deposit, and US Treasury bills, providing sufficient funding for clinical trials and commercialization preparations.

Negative

R&D expenses increased to $10.3 million from $6.8 million year-over-year, primarily due to the Dragon and Phoenix trials.
G&A expenses rose significantly to $12.7 million from $2.9 million, driven by share-based compensation expenses.
The company reported a net loss of $21.7 million, compared to a net loss of $8.7 million in the same period last year.
Belite Bio Inc (BLTE) has not yet submitted applications to regulatory agencies in China and the UK, with plans to do so in the first half of 2026.
The timeline for submitting applications to multiple countries, including Japan, remains uncertain, potentially delaying market entry.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BLTE.OQ - Belite Bio Inc
Q3 2025 Belite Bio Inc Earnings Call
Nov 10, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for joining us and welcome to the B Light Bio 3rd quarter 2025 earnings call.

After today's prepared remarks, we will host a question-and-answer session.

If you would like to ask a question, please raise your hand.

If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute.

I will now hand the call over to Julie Fallon. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, everyone.

Thank you for joining us.

On the call today are Doctor Tom Lynn,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.